YTHDC2

Across TCGA pan-cancer cohorts, YTHDC2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated YTHDC2 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher YTHDC2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated YTHDC2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and MESO show a favorable association.

UCEC, BRCA, and LIHC are the cancer types where YTHDC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.975	0.602	.001	36	view →
BRCA	OS	Median	All	0.583	0.924	<.001	34	view →
LIHC	DFS	Median	All	0.081	0.527	.012	15	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
SARC	DFS	Median	All	0.121	0.613	.001	6	view →
SCLC	OS	Median	All	0.082	0.653	.002	6	view →
MESO	DFS	Median	All	1.000	0.179	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

YTHDC2–UCEC (DFS)

Open the UCEC breakdown →